Futura Medical plc (AIM: FUM), the pharmaceutical company developing innovative sexual health products, is pleased to announce its unaudited interim results for the six months ended 30 June 2023 (“H1 2023”). MED3000, under the brand name Eroxon®, is the first pan-European clinically proven topical treatment for Erectile Dysfunction (“ED”) available without the need of a doctor’s prescription […]
No-one is likely to forget the tragic events of 2020 and one company leading efforts to prepare for the next pandemic is Poolbeg Pharma. Optimum Strategic Communications’ Richard Staines interviewed CEO Jeremy Skillington to find the latest insights. Discussions are not about whether another pandemic will happen, but when, as a number of factors converge […]
Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology focused on sexual health, announces that Non-Executive Chairman, John Clarke has stepped down and is succeeded by existing Non-Executive board member, Jeff Needham. Read more…
Recently acquired Sanofi portfolio products to be combined with acquired Libber Pharma infrastructure to build new affiliate in Brazil Products in Mexico to be distributed through newly established greenfield affiliate Barcelona and Düsseldorf – July 11, 2023 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) […]
Laboratorios Lesvi is Neuraxpharm’s manufacturing facility for Finished Dosage Forms (FDF) in Spain Barcelona and Dusseldorf – May 4, 2023 – Neuraxpharm Group (Neuraxpharm), the leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces that it has rebranded Laboratorios Lesvi to create Neuraxpharm Pharmaceuticals S.L. Read more…
